Total Payments
$2,928
2024 Payments
$2,064
Companies
33
Transactions
166
Medicare Patients
1,398
Medicare Billing
$569,742
Payment Breakdown by Category
Food & Beverage$2,818 (96.2%)
Education$109.99 (3.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,818 | 164 | 96.2% |
| Education | $109.99 | 2 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $444.25 | 37 | $0 (2024) |
| Celgene Corporation | $258.51 | 19 | $0 (2024) |
| PFIZER INC. | $256.96 | 15 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $230.68 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $211.04 | 9 | $0 (2024) |
| Gilead Sciences, Inc. | $142.68 | 7 | $0 (2024) |
| ABBVIE INC. | $137.08 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $129.43 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $110.46 | 5 | $0 (2024) |
| Genentech USA, Inc. | $101.18 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,064 | 122 | E.R. Squibb & Sons, L.L.C. ($302.59) |
| 2023 | $846.38 | 43 | E.R. Squibb & Sons, L.L.C. ($141.66) |
| 2022 | $17.32 | 1 | Celgene Corporation ($17.32) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Oncology | ||||||
| 12/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| 12/18/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $9.28 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.13 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.83 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: BioOncology | ||||||
| 11/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $8.43 | General |
| Category: Hematology | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.37 | General |
| Category: Hematology | ||||||
| 11/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.81 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Oncology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| Category: Oncology | ||||||
| 10/21/2024 | PFIZER INC. | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: Oncology | ||||||
| 10/03/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.10 | General |
| Category: Hematology | ||||||
| 09/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.16 | General |
| 09/16/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $8.69 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,398 | 40,828 | $2.4M | $569,742 |
Total Patients
1,398
Total Services
40,828
Medicare Billing
$569,742
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 8,000 | $1.2M | $352,059 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 27 | 2,940 | $214,440 | $53,987 | 25.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 35 | 14,050 | $295,050 | $32,414 | 11.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 27 | 27 | $102,485 | $28,014 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 244 | $54,656 | $22,853 | 41.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 107 | 166 | $113,876 | $14,899 | 13.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 44 | 45 | $53,536 | $8,344 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 48 | 48 | $20,736 | $7,555 | 36.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 50 | $15,050 | $6,583 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 87 | $12,876 | $5,721 | 44.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 23 | 3,900 | $35,100 | $5,308 | 15.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $12,005 | $4,195 | 34.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 33 | $7,656 | $2,951 | 38.5% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 45 | 45 | $39,401 | $2,731 | 6.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 20 | $8,240 | $2,607 | 31.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 47 | $15,698 | $2,090 | 13.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 23 | 39 | $7,995 | $1,956 | 24.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 42 | $12,768 | $1,858 | 14.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 19 | 19 | $12,122 | $1,788 | 14.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 29 | $4,553 | $1,723 | 37.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 47 | 78 | $11,856 | $1,582 | 13.3% |
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 11 | 17 | $11,237 | $1,471 | 13.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 64 | 118 | $12,390 | $1,279 | 10.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 81 | 100 | $9,300 | $1,016 | 10.9% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 12 | 12 | $9,357 | $889.28 | 9.5% |
About Dr. Alexandre Tungesvik, M.D
Dr. Alexandre Tungesvik, M.D is a Hematology & Oncology healthcare provider based in Columbia, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2017. The National Provider Identifier (NPI) number assigned to this provider is 1538691381.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexandre Tungesvik, M.D has received a total of $2,928 in payments from pharmaceutical and medical device companies, with $2,064 received in 2024. These payments were reported across 166 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($2,818).
As a Medicare-enrolled provider, Tungesvik has provided services to 1,398 Medicare beneficiaries, totaling 40,828 services with total Medicare billing of $569,742. Data is available for 1 year (2023–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Columbia, MO
- Active Since 03/31/2017
- Last Updated 02/17/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538691381
Products in Payments
- OPDIVO (Biological) $283.81
- REBLOZYL (Biological) $219.72
- KEYTRUDA (Biological) $211.04
- IBRANCE (Drug) $115.53
- OPDUALAG (Drug) $104.76
- SCEMBLIX (Drug) $94.66
- Enhertu (Drug) $83.50
- CABOMETYX (Drug) $81.09
- VENCLEXTA (Drug) $75.53
- ENHERTU (Biological) $69.61
- KRAZATI (Drug) $55.68
- LUTATHERA (Drug) $52.58
- XTANDI (Drug) $52.54
- ELAHERE (Drug) $46.57
- Lenvima (Drug) $46.46
- IMFINZI (Biological) $43.34
- BOSULIF (Drug) $41.41
- Pomalyst (Drug) $38.79
- OJJAARA (Drug) $36.38
- RYBREVANT (Drug) $35.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Columbia
David Schlossman, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Dr. Gerhard Hildebrandt, Md, MD
Hematology & Oncology — Payments: $63,845
Hematology & Oncology $63,845
Umasankar Ramadoss, Md, MD
Hematology & Oncology — Payments: $46,134
Hematology & Oncology $46,134
Donald Doll, Md, MD
Hematology & Oncology — Payments: $33,506
Hematology & Oncology $33,506
Dr. Fred Kudrik, Md, MD
Hematology & Oncology — Payments: $25,867
Hematology & Oncology $25,867
Dr. Andrew Iliff, Md, MD
Hematology & Oncology — Payments: $21,631
Hematology & Oncology $21,631